Please assess the completion status of the following clinical trial:

Trial Title: CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 11.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Metastatic cancer with evaluable disease.~ 2. Patients must have previously received at least one systemic standard care (or effective salvage chemotherapy regimens) for metastatic disease, if known to be effective for that disease, and have been either non-responders (progressive disease) or have recurred.~ 3. Greater than or equal to 18 years of age and less than or equal to 70 years of age.~ 4. Willing to sign a durable power of attorney~ 5. Able to understand and sign the Informed Consent Document~ 6. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.~ 7. Life expectancy of greater than three months.~ 8. Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment.~ 9. Serology:~     1. Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities.)~    2. Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by reverse transcription-polymerase chain reaction (RT-PCR) and be hepatitis C virus (HCV) ribonucleic acid (RNA) negative.~ 10. Hematology:~      1. Absolute neutrophil count greater than 1000/mm(3) without the support of filgrastim.~     2. White blood cell (WBC) (\> 3000/mm(3)).~     3. Platelet count greater than 100,000/mm(3).~     4. Hemoglobin greater than 8.0 g/dl.~ 11. Chemistry:~      1. Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less or equal to 2.5 times the upper limit of normal.~     2. Serum creatinine less than or equal to 1.6 mg/dl.~     3. Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilberts Syndrome who must have a total bilirubin less than 3.0 mg/dl.~ 12. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).~ 13. More than 4 weeks must have elapsed since an surgical procedure at the time the patient receives the preparative regimen due to the inhibition of wound healing observed with vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors.~EXCLUSION CRITERIA:~1. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.~2. Patients with known brain metastases.~3. Patients receiving full dose anticoagulative therapy.~4. Active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease.~5. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).~6. Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities).~7. Patients with diabetic retinopathy.~8. Concurrent Systemic steroid therapy.~9. History of severe immediate hypersensitivity reaction to any of the agents used in this study.~10. History of coronary revascularization or ischemic symptoms.~11. In patients~Documented forced expiratory volume 1 (FEV1) less than or equal to 45% predicted tested in patients with:~1. History of ischemic heart disease, chest pain, or clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block.~2. Age greater than or equal to 60 years old.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (1x10(6) cells (high dose IL-2) (Type: EXPERIMENTAL): Patients will receive (1x10(6) cells plus high dose aldesleukin
- Cohort 2 (3x10(6) cells (high dose IL-2) (Type: EXPERIMENTAL): Patients will receive (3x10(6) cells plus high dose aldesleukin
- Cohort 3 (1x10(7) cells (high dose IL-2) (Type: EXPERIMENTAL): Patients will receive (1x10(7) cells plus high dose aldesleukin
- Cohort 4 (3x10(7) cells (high dose IL-2) (Type: EXPERIMENTAL): Patients will receive (3x10(7) cells plus high dose aldesleukin
- Cohort 5 (1x10(8) cells (high dose IL-2) (Type: EXPERIMENTAL): Patients will receive (1x10(8) cells plus high dose aldesleukin
- Cohort 6 (3x10(8) cells (high dose IL-2) (Type: EXPERIMENTAL): Patients will receive (3x10(8) cells plus high dose aldesleukin
- Cohort 7 (1x10(9) cells (high dose IL-2) (Type: EXPERIMENTAL): Patients will receive (1x10(9) cells plus high dose aldesleukin
- Cohort 8 (1x10(9) cells (low dose IL-2) (Type: EXPERIMENTAL): Patients will receive (1x10(9) cells plus low dose aldesleukin
- Cohort 9 (3x10(9) cells (low dose IL-2) (Type: EXPERIMENTAL): Patients will receive (3x10(9) cells plus low dose aldesleukin
- Cohort10(1x10(10) cells (low dose IL-2) (Type: EXPERIMENTAL): Patients will receive (1x10(10) cells plus low dose aldesleukin
- Cohort11(3x10(10) cells (low dose IL-2) (Type: EXPERIMENTAL): Patients will receive (3x10(10) cells plus low dose aldesleukin

Based on this trial design, predict the completion outcome and termination type (if applicable).